CBD oil stock is rising, both metaphorically, in the eyes of the public-at-large, and literally, as the industry readies itself to near the $2 billion mark sometime in the next decade. As such, more research continues to be dedicated to learning about and understanding the power and benefits of cannabidiol.
CBD oil popularity among sports enthusiasts continues to grow at an astounding pace, with some professional athletes going so far as to launch lines of CBD products. Still, most professional leagues ban their athletes from using CBD oil, too afraid to brush up against the federal government and the confusing laws that govern CBD.
FDA officials finally approved the world’s first CBD-based drug, Epidiolex, developed by pharmaceutical-maker by GW Pharmaceuticals. The drug is designed for use in treating two severe forms of childhood epilepsy and is the very first FDA-approved medication that contains a purified cannabinoid derived from cannabis. Moreover, it is the first FDA approval of any drug specifically meant to treat Dravet syndrome, one of the aforementioned forms of epilepsy.
Quite often patients diagnosed with ADHD are prescribed stimulants such as Adderall, Ritalin, Concerta, and Vyvanse all of which can have unwanted side effects. But recent research suggests that CBD may provide some relief for those who have ADHD. CBD may also be helpful in mitigating some of the side effects that come with prescription medications.
A clinical study on CBD involving humans (not lab animals) is expected to be completed in May. The purpose of the study is to “evaluate the abuse potential of CBD to determine whether it should remain as a Schedule I drug under the Controlled Substances Act, or be recommended for decontrol.”